Core Insights - ClearBridge Investments reported a significant rally in US equities during Q2 2025, with the S&P 500 returning 10.9% and the Russell Midcap Growth Index advancing 18.2% [1] - The ClearBridge Growth Strategy outperformed its benchmark, driven by strong performance in the "mid cap plus" segment and solid stock selection in IT, industrials, and financials [1] Company Overview: Charles River Laboratories International, Inc. (CRL) - Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services through various segments [2] - The stock experienced a one-month return of 5.00% and a 52-week gain of 26.44%, closing at $151.60 with a market capitalization of $7.461 billion on September 16, 2025 [2] Investment Strategy and Performance - ClearBridge Growth Strategy closed positions in MongoDB and Charles River Laboratories to focus on higher-conviction growth names due to a challenging biotech funding environment and regulatory risks [3] - The company reported revenue of $1.03 billion in Q2 2025, reflecting a 0.6% increase from Q2 2024 [4] - Despite the potential of Charles River Laboratories, the company is not among the 30 most popular stocks among hedge funds, with 49 hedge fund portfolios holding the stock at the end of Q2 2025, up from 39 in the previous quarter [4]